Risk-reduction surgery in BRCA mutation carriers in a Spanish population: Adherence and results

Clinical and Translational Oncology

Volumn 10, Issue 10, 2008, Pages 660-664

  Segura, Pedro Pérez ^a   Jiménez, Paula ^a   Olivera, Helena ^a   Conejero, Raquel Andrés ^c   Caldés, Trinidad ^a   De La Hoya, Miguel ^a   Román, Jose María ^a   Moreno, Arancha ^a   Puente, Javier ^a,b   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

BRCA; Prophylactic surgery; Spanish

Indexed keywords

ADULT; ARTICLE; BREAST TUMOR; CARCINOMA; FAMILY; FEMALE; GENETIC COUNSELING; GENETICS; HETEROZYGOTE; HUMAN; METHODOLOGY; MUTATION; OVARY TUMOR; PATIENT COMPLIANCE; POPULATION; PREVENTIVE MEDICINE; PSYCHOLOGICAL ASPECT; SPAIN; STATISTICS; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; CARCINOMA; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PATIENT COMPLIANCE; POPULATION; PREVENTIVE MEDICINE; SPAIN;

EID: 58149377804     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0267-9     Document Type: Article

References (30)

1. Mik Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
2. Wooster R, Bignell G, Swift S et al (1995) Identification of BRCA2 gene. Nature 378:789-792
3. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the NSABP P-1 study. J Natl Cancer Inst 90:1371-1388
4. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for prevention of breast cancer: current status of the NSABP P-1 study. J Natl Can cer Inst 97:1652-1662
5. Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital. Tamoxifen randomised chemoprevention trial. Lancet 352:98-101
6. Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian Tamoxifen Prevention Study. Lancet 352:93-97
7. Cuzick T, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast cancer prevention trials. Lancet 361:296-300
8. Cauley JA, Norton L, Lippmann ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifen: 4-year results from the MORE trial. Multiple outcomes of raloxifen evaluation. Breast Cancer Res Treat 65:125-134
9. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations of BRCA1 and BRCA2. JAMA 286:2251-2256
10. Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 and BRCA2 mutation: a critical review of the literature. Int J Cancer 112:357-364
11. Narod SY, Brunet JS, Ghadinan P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a casecontrol study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881
12. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM et al (2005) Use of statins and breast cancer: a metaanalysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606-8612
13. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055-1062
14. Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1 and BRCA2 mutations: an updates decision analysis. J Clin Oncol 20:2520-2529
15. Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of prophylactic mastectomy in women with family of breast cancer. N Engl J Med 340: 77-84
16. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615
17. Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38:15-17
18. Boughey JC, Khakpom N, Meric-Bernstam F et al (2006) Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107:1440-1447
19. Julian-Reynier CM, Bouchard LJ, Evans DG et al (2001) Women's attitudes towards preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French and Canadian women. Cancer 92:959-968
20. Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637
21. Meijers-Heijboer H, van Geel B, van Putten WL (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 and BRCA2. N Engl J Med 345:159-164
22. Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast examination. JAMA 292:1317-1325
23. Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population al high familiar risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778
24. Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breastcancer screening in women with a familiar or genetic predisposition. N Engl J Med 351:427-437
25. Brekelmans CT, Seynaeve C, Bartels CM et al (2001) Effectiveness of breast cancer surveillance in BRCA1 and BRCA2 gene mutation carriers and wo men with high familiar risk. J Clin Oncol 19:924-930
26. Lehmen CD, Blume JD, Weatherall P et al (2005) Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103:1898-1905
27. Bourne TH, Campell S, Reynolds KM et al (1993) Screening for early familiar ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306:1025-1029
28. Scheuer L, Kauff N, Robson M et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268
29. Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/ 2 mutations: an updated decision analysis. J Clin Oncol 20:2520-2529
30. Society of Gynecologic Oncologists Clinical Practice Committee (2005) Statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98:179-181